About us

HAEMATO — Well Established

HAEMATO and all its employees are primarily oriented towards the needs of patients and customers in their daily work. Service, quality and reliability are essential elements of our customer orientation and at the same time drivers of further growth.

We will be happy to answer any questions or specific concerns you may have.

Ordering Service Germany

Phone 030 / 677 9867 – 600
Fax 030 / 677 9867 – 707

Ordering Service Austria

Phone 0800 / 293 527
Fax 0800 / 296 426

2,430 m² total area at locations Schönefeld and Berlin-Bohnsdorf

More than 7,000 customers

60 employees

28 apprentices since foundation

67 % female employees

For more than15 years, HAEMATO has been committed to actively help reduce costs in the healthcare system so that every patient can benefit from the latest therapies and treatment options, even if these are often very expensive.

With our product portfolio of off-patent and patent-protected pharmaceuticals, we contribute to an efficient supply of medicines, reducing costs for health insurance companies and thus for patients.

In the area of our own brands, the focus is on development, acquisition, licensing and distribution of prescription drugs and OTC products, special cosmetics as well as dietary supplements in the lifestyle and aesthetics sector.

Products and services of the medical-aesthetic market are increasingly in demand. Society, which is getting older and staying fit longer, wants to look their perceived age. Also due to the increased social acceptance of beauty medicine, the beauty market is a growing branch within the health market.

News

Find out about the current business development of HAEMATO AG as well as about our investor relations activities.

To the news archive

interim report

Ad-Hoc Mitteilung

Berlin, November 30, 2023: The Management Board of HAEMATO AG ("Company"; ISIN: DE000A289VV1/ Open Market / Basic Board) has decided today, November 30, 2023, with the approval of the Supervisory Board, to terminate the inclusion of the Company's shares in the Open Market (Basic Board) on the Frankfurt Stock Exchange pursuant to Section 30 of …

interim report

Investor News

In the first nine months of the 2023 financial year, preliminary IFRS consolidated sales rose by around 13% to EUR 212.2 million compared to the same period in 2022 (EUR 188.2 million). The result from ordinary activities (EBITDA) increased strongly by around 33% from EUR 7.7 million to EUR 10.2 million. The operating result (EBIT) even increased …

interim report

Ad-Hoc Mitteilung

Berlin, 15. November 2023 – Due to new findings on changed market conditions, an updated validation of the profitability of the company's own botulinum toxin project was carried out.  After reviewing various options, the Executive Board decided today to terminate the cooperation with the Korean manufacturer Huons BioPharma and to …

We are here for you.

Ordering Service Germany

Phone 030 / 677 9867 – 600
Fax 030 / 677 9867 – 707

Ordering Service Austria

Phone 0800 / 293 527
Fax 0800 / 296 426

HAEMATO Shop

PoC Testing Devices, Antigen Rapid Tests, FFP2 Masks
www.schnelltest-antigen.de

M1 SELECT Shop

Acitive igredients cosmetics | Medical skincare developed by doctors
m1-select.de/en/